A comprehensive review of rituximab therapy in rheumatoid arthritis patients

Soheil Tavakolpour(Shahid Beheshti University of Medical Sciences), ‬‬Samira Alesaeidi(Tehran University of Medical Sciences), Mohammad Darvishi(Aja University of Medical Sciences), Mojtaba Ghasemiadl(Tehran University of Medical Sciences), Sahar Darabi-Monadi(Mashhad University of Medical Sciences), Meisam Akhlaghdoust(Iran University of Medical Sciences), Somayeh Elikaei Behjati(Islamic Azad University, Science and Research Branch), Arash Jafarieh(Tehran University of Medical Sciences)
Clinical Rheumatology
August 1, 2019
10.1007/s10067-019-04699-8
Cited by 115

Abstract

Related Papers

Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry
Jacques‐Eric Gottenberg, Philippe Ravaud, Thomas Bardin et al.|Arthritis & Rheumatism|2010|300
Rituximab‐Induced T Cell Depletion in Patients With Rheumatoid Arthritis: Association With Clinical Response
J Melet, Denis Mulleman, Philippe Goupille et al.|Arthritis & Rheumatism|2013|162
Improvement in patient‐reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti–tumor necrosis factor therapy
Edward Keystone, Gerd R Burmester, R. Furie et al.|Arthritis Care & Research|2008|105
Rituximab or a second anti–tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti–tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register
Moetaza M. Soliman, Kimme L Hyrich, Mark Lunt et al.|Arthritis Care & Research|2012|85
Low‐ Versus High‐Dose Rituximab for Rheumatoid Arthritis: A Systematic Review and Meta‐Analysis
Markus Bredemeier, Fernando K. de Oliveira, Cláudia Monfroni Rocha|Arthritis Care & Research|2013|78